An interventional study of 30% Nitrous oxide and 0.4% Sevoflurane in Opioid-Related Disorders and Substance-Related Disorders, sponsored by University of Chicago. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2015-05-27.
Sponsored by University of Chicago · Not applicable, Interventional, and Treatment
The purpose of this study is to determine the effects of combined sevoflurane and nitrous oxide inhalation on mood, psychomotor performance, and the pain response in humans.
2,124 studies on the registry are indexed under Substance-Related Disorders; 393 are open to participants now.
This study's enrollment of 20 is below the median of 108 across 1,727 interventional studies indexed under Substance-Related Disorders.
Browse Substance-Related Disorders studies →University of Chicago is the lead sponsor of 907 studies on the registry; 182 are open to participants now.
Of its 99 completed or terminated interventional studies of FDA-regulated products, 68 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Please contact site for information.
Drug: 30% Nitrous oxide · Other: Placebo
Drug: 30% Nitrous oxide · Drug: 0.2% sevoflurane
Drug: 30% Nitrous oxide · Drug: 0.4% Sevoflurane
Pain intensity, pain bothersomeness
Inhalation was for 68 min divided into 4 blocks with nitrous oxide added during either block 2 or block 4
Time frame: During inhalation
Mood
Inhalation was for 68 min divided into 4 blocks with nitrous oxide added during either block 2 or block 4
Time frame: During inhalation
Psychomotor performance
Inhalation was for 68 min divided into 4 blocks with nitrous oxide added during either block 2 or block 4
Time frame: During inhalation
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Chicago